今日港股走势分化，医药产业链股集体大涨，大型互联网股表现活跃，截至收盘，中证港股通医药卫生 综合指数上涨4.0%，中证港股通互联网指数上涨1.3%，恒生港股通新经济指数上涨1.0%，恒生科技指 数上涨0.1%，中证港股通消费主题指数下跌0.4%。 2. 银行,互联网平台等相关照售机构提供可场外投资的EF联接基金。 注3) 從看到六部,其德理都清0.124/英。托瑟曼塞(0.00V)体 华泰证券表示，上周港股在科技催化驱动下收涨，2026年首个交易日实现"开门红"。当前市场情绪、资 金面环境比11月更优，布局港股胜率提升，建议一方面继续配置有业绩兑现预期的科技链，在流动性环 境催化下一季度或有高斜率空间，同时考虑到驱动因素和资金属性变化，做现金流资产的均衡配置。 24.0% 港股通消费ETF易方达 低费率 513070 跟踪中证港股通消费主题指数 该指数自2020年 今日 该指数 该指数由港股通范围内流动性 该指数涨跌 滚动市盈率 发布以来估值分位 较好、市值较大的50只消费主 题股票组成,可选消费占比近 -0. 4% 16.9倍 0. 0% 60% 注1 "训练教"排名上述基金产品周体用润的热度。数据录,fa ...

Core Viewpoint - The launch of the Sci-Tech Innovation Board Composite Index (Sci-Tech Index) marks a significant development in the A-share market, with the index being considered for inclusion as one of the "four major indices" alongside the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index, reflecting the growing importance of the Sci-Tech sector in China's economy [3][4][5]. Group 1: Importance of the Sci-Tech Index - The Sci-Tech Index has shown a growth of approximately 48% since its launch on January 20, 2025, and a cumulative increase of 115% since September 24, 2024, indicating strong market performance [3]. - The index has attracted significant interest, with 46 fund managers launching 78 index funds related to the Sci-Tech Index, accumulating a total scale of 27.4 billion yuan [3][12]. - Experts believe that the inclusion of the Sci-Tech Index will enhance the A-share market's index system, providing a comprehensive representation of the technology sector and filling a critical gap in the existing index framework [4][9]. Group 2: Structural Differences and Complementarity - The Sci-Tech Index covers 576 stocks, achieving a coverage rate of 96% within the Sci-Tech Board, while the other major indices have different coverage and industry weightings, creating a complementary relationship among them [7][9]. - The industry weightings reveal that the Sci-Tech Index has a dominant focus on information technology (54.63%), contrasting with the other indices that emphasize traditional sectors or different technology applications [7][8]. - The four indices together create a multi-layered, differentiated core index system for the A-share market, each serving distinct functions and contributing to a collaborative ecosystem [8][9]. Group 3: Investment Logic Shift - The investment logic is shifting from a "profit-oriented" approach to an "innovation-driven" model, reflecting the unique characteristics of hard technology assets that require a different valuation paradigm [10][12]. - Investors are encouraged to focus on long-term growth potential and technological breakthroughs for hard technology assets, while traditional assets should emphasize stable cash flows and dividend capabilities [12][13]. - The Sci-Tech Index's high valuation compared to other indices is not seen as a bubble but rather a reflection of the unique attributes of hard technology investments, which involve high R&D costs and long-term returns [11][12]. Group 4: Future Outlook and Development - The Sci-Tech Index is expected to continue gaining attention and importance in the capital market over the next 3-5 years, with potential to become a global benchmark for China's technological innovation [19]. - Enhancements in the index's composition and governance will be crucial for its global recognition and influence, as well as attracting domestic and international long-term investors [19]. - The index's ability to represent China's "new quality productivity" and its alignment with national strategic directions will further solidify its role as a core asset allocation tool for technology investments [16][18].

Core Viewpoint - The Sci-Tech Innovation Board Composite Index (Sci-Tech Index) has shown significant growth since its launch, reflecting the overall development of China's technology innovation sector and attracting substantial investment [3][4][6]. Group 1: Performance and Coverage - The Sci-Tech Index has increased by 48.35% since its launch on January 20, 2025, outperforming major market indices [3][8]. - The index currently includes 576 stocks, covering 96% of the Sci-Tech Board companies, with a market capitalization coverage of over 91% [7][9]. - The total market capitalization of the Sci-Tech Board reached 11.14 trillion yuan, with the 576 stocks in the index accounting for 10.18 trillion yuan, or 91.38% of the total [7][9]. Group 2: Industry Composition - The index includes stocks from various sectors, with the largest representation from information technology (54.86%), followed by industrial (23.14%) and healthcare (13.50%) [7][9]. - The top ten stocks in the index represent 27.5% of its total market capitalization, with ten stocks exceeding 100 billion yuan in market value [7][9]. Group 3: Investment Products and Ecosystem - As of December 24, 2025, 45 fund managers have launched 77 index funds related to the Sci-Tech Index, with a total scale of 27 billion yuan [10][11]. - The average return of these products since their launch has been 42%, indicating strong investor interest [11]. - The index has facilitated a one-stop investment tool for investors, enhancing the accessibility of "hard technology" investments [11][12]. Group 4: Future Development and Optimization - Experts suggest that the Sci-Tech Index should continuously optimize its dynamic adjustment and maintenance mechanisms to reflect the latest developments in the hard technology sector [5][13]. - There is a need to enhance the scientific and representative nature of the index, focusing on key indicators such as R&D investment intensity and technology transfer capabilities [12][13]. - The index is expected to play a crucial role in guiding long-term capital allocation and enhancing recognition of China's technological strength among domestic and foreign investors [16][17].

Core Insights - The STAR Market Composite Index (科创综指) has significantly increased by 48.35% since its launch on January 20, 2025, outperforming major broad market indices [1][4][5] - The index currently includes 576 sample stocks, covering 96% of the STAR Market companies, with a market capitalization coverage exceeding 91% [3][4] - The total market capitalization of the STAR Market has reached 11.14 trillion yuan, with the 576 stocks in the index accounting for 10.18 trillion yuan, or 91.38% of the total [3][5] Index Performance and Structure - The STAR Market Composite Index has a diverse representation across various sectors, with 202 stocks from the industrial sector, 199 from information technology, and 107 from healthcare [3] - The index's top ten stocks represent 27.5% of its total market capitalization, with ten stocks exceeding 100 billion yuan in market value [3][4] - The index has been supported by improved industry fundamentals, policy benefits, and active capital inflows, reflecting a shift from emotional recovery to trend-driven growth [4][5] Investment Products and Ecosystem - As of December 24, 2025, 45 fund managers have launched 77 STAR Market Composite Index funds, with a total scale of 27 billion yuan [6] - The average return of these products since their launch has been 42%, indicating strong investor interest and confidence in the index [6] - The index serves as a convenient investment tool for institutional investors, allowing them to efficiently allocate capital to the "hard technology" sector [6][7] Future Development and Optimization - Experts suggest that the STAR Market Composite Index should continuously optimize its dynamic adjustment and maintenance mechanisms to reflect the latest developments in the hard technology sector [2][7] - There is a need to enhance the scientific and representative nature of the index, focusing on key indicators such as R&D intensity and technology transfer capabilities [6][10] - The index is expected to play a crucial role in guiding long-term capital allocation and enhancing recognition of China's technological strength among domestic and foreign investors [9][10]

Market Overview - The A-share pharmaceutical sector opened lower and continued to decline, while the Hong Kong pharmaceutical sector showed signs of recovery in the afternoon, with a significant narrowing of losses [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 0.8%, the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 0.9%, the China Securities Biotechnology Theme Index dropped by 1.5%, the CSI 300 Pharmaceutical and Health Index declined by 1.7%, and the China Securities Innovative Drug Industry Index fell by 1.9% [1] Fund Activity - Despite the market downturn, there was a counter-trend investment with the Hang Seng Innovative Drug ETF (159316) seeing a net subscription of approximately 20 million units throughout the day [1]

Group 1 - The pharmaceutical sector continues to adjust, with various indices such as the Hang Seng Innovative Drug Index and the CSI Hong Kong Pharmaceutical and Health Comprehensive Index declining by 1.2% [1] - Despite the downturn, there is a significant capital inflow, with the Hang Seng Innovative Drug ETF (159316) seeing a net subscription of over 80 million units throughout the day [1] - The fundamental reason for the pharmaceutical industry's ability to reach new highs despite ongoing challenges is the persistent demand for pharmaceuticals and the increasing number of unmet needs, alongside continuous R&D investments by pharmaceutical companies [1] Group 2 - China has become a significant player in global innovative drug research and development, with overseas licensing activity continuing to rise year after year [1] - The pharmaceutical industry is entering a revenue era driven by innovation [1]

医疗ETF（159828）跟踪的是中证医疗指数（399989），该指数从沪深市场中选取医药卫生和药品零售 行业的上市公司证券作为指数样本，主要覆盖医疗器械、医疗服务及医疗研发外包等领域，以反映医疗 主题相关上市公司证券的整体表现。该指数成分股偏向中小市值，具有较高的成长性与波动性特征。 （文章来源：每日经济新闻） 国金证券表示，REDEMPLO获批，CNS领域突破，Arrowhead如箭在弦。小核酸领域领军公司 Arrowhead制药上周市值上涨16.6亿美元。2025年11月18日，公司的第一款小核酸产品Plozasiran获FDA 批准上市，这标志着公司步入商业化兑现的历史新阶段。同时，公司在研产品正在向更大患者市场的慢 病与中枢神经系统领域推进。 医疗ETF（159828）连续5日迎净流入，小核酸进军慢病，如箭在弦。 ...

Group 1 - The pharmaceutical sector experienced a decline today, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index down by 1.3%, the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 1.4%, the CSI 300 Pharmaceutical and Health Index down by 1.5%, the CSI Innovative Drug Industry Index down by 1.6%, and the CSI Biotechnology Theme Index down by 1.8% [1] - Huachuang Securities stated that the fundamental reason for the pharmaceutical industry's ability to reach new highs despite ongoing challenges is the continuous demand for pharmaceuticals and the increasing number of unmet needs, along with pharmaceutical companies continuously increasing R&D investments to meet these demands [1] - China has become a significant participant in global innovative drug R&D, with overseas licensing heat continuing to rise year after year, marking the pharmaceutical industry’s entry into a revenue era driven by innovation [1] Group 2 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug R&D, gathering the main players in A-share innovative drugs [5] - The index has seen a decline of 1.6%, with a rolling price-to-earnings ratio of 50.2 times and a valuation increase of 72.8% since its launch [6] - The biotechnology ETF tracks the CSI Biotechnology Theme Index, which focuses on leading biotechnology companies in the A-share market, consisting of no more than 50 stocks involved in gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [7] - The biotechnology index has declined by 1.8%, with a rolling price-to-earnings ratio of 54.7 times and a valuation increase of 63.4% since its launch [8] - The pharmaceutical ETF exclusively tracks the CSI 300 Pharmaceutical and Health Index, focusing on leading companies in the pharmaceutical and health industry within the CSI 300 Index, covering various segments of the future health industry [9] - The pharmaceutical index has declined by 1.5%, with a rolling price-to-earnings ratio of 30.4 times and a valuation increase of 43.1% since its launch [10]

Core Viewpoint - The new standards to be implemented in December focus on enhancing detection regulations in key sectors such as electronics, food, and energy, utilizing advanced instrumentation technologies like ICP spectroscopy and liquid chromatography to promote quality improvement and green transformation across industries [2][3]. Group 1: Overview of New Standards - Over 700 new standards will be implemented in December, covering critical areas including food, agriculture, environment, healthcare, petroleum, electronics, transportation, and machinery [3]. - The release and implementation of these standards aim to realize the concept of "quality improvement and efficiency enhancement," supporting technological upgrades and quality enhancement for high-quality economic development [3]. Group 2: Advanced Analytical Techniques - Advanced analytical methods such as ICP-OES for measuring lead, phosphorus, and zirconium content, HPLC for determining bitter acid, and atomic fluorescence spectroscopy for measuring mercury and arsenic are widely adopted in chemical and fireworks detection projects [5]. - The power industry standards include methods for measuring anions in water vapor using ion chromatography [5]. Group 3: Food Safety and Biological Testing - New standards involve liquid chromatography-tandem mass spectrometry for detecting isothiazolinone compounds in feed, and rapid quantitative methods for grain toxins using fluorescence immunochromatography and colloidal gold [6]. - The biological field includes regulations for real-time quantitative PCR detection technology [6]. Group 4: Environmental and Physical Performance Monitoring - Standards cover methods for observing atmospheric particulate matter (PM10, PM2.5) using light scattering, testing radiation protection instrument performance, and measuring fuel calorific value using bomb calorimetry [6]. - Non-destructive testing guidelines have been introduced in the power and machinery sectors, including array eddy current, phased array ultrasound, and acoustic imaging detection technologies [6]. Group 5: Specific New Standards for December 2025 - A detailed list of new standards includes 96 standards related to agriculture and food, such as guidelines for classification and grading of agricultural products, and technical regulations for the cultivation and harvesting of Ganoderma [7]. - Additional standards cover various aspects of food safety, environmental protection, and industrial practices, reflecting a comprehensive approach to quality and safety across multiple sectors [8][9].

Group 1: Economic Development Strategy - The "15th Five-Year Plan" aims to achieve significant progress in modernizing Guangxi alongside the nation, focusing on high-quality development [1] - The plan emphasizes the importance of political responsibility and innovation to ensure effective implementation [1][2] - The strategy includes enhancing economic reforms to drive high-quality development and address new challenges [2][3] Group 2: Industrial and Technological Advancement - Guangxi plans to leverage its unique geographical and resource advantages to develop advanced manufacturing and become a key industrial base [3] - The region will focus on integrating artificial intelligence and modernizing ten key industries to boost economic growth [3] - The contribution of high-tech manufacturing to tax revenue has been increasing, indicating a positive trend in economic vitality [3] Group 3: Taxation and Financial Management - The tax system will focus on compliance and risk management to ensure stable revenue generation while fostering new tax sources [4] - Policies will be tailored to support industries like artificial intelligence and green development, enhancing the precision of tax incentives [4] - The tax authority aims to improve the business environment and support local enterprises in enhancing international competitiveness [4] Group 4: Cultural and Tourism Development - The plan aims to stimulate cultural innovation and create a strong cultural tourism sector, enhancing Guangxi's global appeal [5] - The region's forestry industry is projected to exceed 1.069 trillion yuan in output value by 2024, showcasing its growth potential [5] Group 5: Health and Social Welfare - The strategy includes improving the social security system and promoting health initiatives to enhance the quality of life for residents [7] - The healthcare system will focus on reforming medical services and integrating technology to improve accessibility and efficiency [8] - Emergency management will prioritize safety and stability, enhancing the region's resilience to risks and disasters [8]